Table 1

Adaptation of the treatment recommendations of EASL and IDSA/AASLD of patients infected with genotype 3 of the hepatitis C virus, without cirrhosis or with compensated cirrhosis. recommended treatments.Update 2018 *†17 18

Genotype 3-infected patientEASL17 IDSA/AASLD18
Naïve-non cirrhoticSOF/VEL 12 w
GLE/PIB 8 w
SOF/VEL 12 w
GLE/PIB 8 w
Treatment experienced-non cirrhotic‡SOF/VEL 12 w
GLE/PIB 12 w
SOF/VEL±RBV 12 w
Naïve-cirrhoticGLE/PIB 12 w
SOF/VEL/VOX 12 w
SOF/VEL 12 w
GLE/PIB 12 w
Treatment experienced-cirrhotic‡SOF/VEL/VOX 12 w
GLE/PIB 16 w
ELB/GRZ+SOF 12 w
SOF/VEL/VOX 12 w
  • *This table is a simplified adaptation. It is recommended to consult the direct references.

  • †Ribavirin addition is recommended in some subgroups of patients.

  • ‡Recommendations in experienced patients are different and vary depending on whether the previous treatment was based on peginterferon or DAAs.

  • AASLD, American Association for the Study of the Liver; EASL, European Association for the Study of the Liver; ELB, elbasvir; GLE, glecaprevir; GRZ, grazoprevir; IDSA, Infectious Diseases Society of America; PIB, pibrentasvir; RBV, ribavirina; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir.